BRCA 1

Is Myriad’s Patent On Breast Cancer Genes Valid?

As Myriad Genetic Laboratories nears its one millionth predictive genetic test for hereditary breast and ovarian cancer, the cost of the test has more than doubled, and the company’s 15-year patent monopoly is being challenged by critics who contend it is stymieing other potentially life-saving screening.

More about: , , , , , , ,